{
    "organizations": [],
    "uuid": "4f6bf76e904229d42130790b8c60b6bd43c8c43f",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/02/26/globe-newswire-collegium-to-host-conference-call-to-discuss-fourth-quarter-2017-financial-results-and-provide-corporate-update.html",
    "ord_in_thread": 0,
    "title": "Collegium to Host Conference Call to Discuss Fourth Quarter 2017 Financial Results and Provide Corporate Update",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "CANTON, Mass., Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, March 7, 2018 at 4:30 p.m. Eastern Time. The Company will discuss its financial results and provide a corporate update.\nConference Call Information:\nTo access the conference call, please dial (888) 698-6931 (U.S.) or (805) 905-2993 (International) and refer to Conference ID: 764-8078. An audio webcast will be accessible from the Investor Relations section of the Company’s website: http://www.collegiumpharma.com/ . An archived webcast will be available on the Company’s website approximately two hours after the event.\nAbou t Collegium Pharmaceutical, Inc.\nCollegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx ® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.\nAbout Xtampza ER\nXtampza ® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.\nContact:\nAlex Dasalla\nadasalla@collegiumpharma.com\nSource:Collegium Pharmaceutical, Inc.",
    "published": "2018-02-27T00:01:00.000+02:00",
    "crawled": "2018-02-27T00:58:14.002+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "canton",
        "collegium",
        "pharmaceutical",
        "nasdaq",
        "coll",
        "announced",
        "today",
        "company",
        "host",
        "conference",
        "call",
        "live",
        "audio",
        "webcast",
        "wednesday",
        "march",
        "eastern",
        "time",
        "company",
        "discus",
        "financial",
        "result",
        "provide",
        "corporate",
        "update",
        "conference",
        "call",
        "information",
        "access",
        "conference",
        "call",
        "please",
        "dial",
        "international",
        "refer",
        "conference",
        "id",
        "audio",
        "webcast",
        "accessible",
        "investor",
        "relation",
        "section",
        "company",
        "website",
        "http",
        "archived",
        "webcast",
        "available",
        "company",
        "website",
        "approximately",
        "two",
        "hour",
        "event",
        "abou",
        "collegium",
        "pharmaceutical",
        "collegium",
        "specialty",
        "pharmaceutical",
        "company",
        "focused",
        "developing",
        "portfolio",
        "product",
        "incorporate",
        "proprietary",
        "deterx",
        "technology",
        "platform",
        "treatment",
        "chronic",
        "pain",
        "disease",
        "deterx",
        "technology",
        "platform",
        "designed",
        "provide",
        "delivery",
        "unique",
        "property",
        "flexible",
        "dose",
        "administration",
        "option",
        "xtampza",
        "er",
        "xtampza",
        "er",
        "collegium",
        "first",
        "product",
        "utilizing",
        "deterx",
        "technology",
        "platform",
        "xtampza",
        "er",
        "oral",
        "formulation",
        "oxycodone",
        "approved",
        "fda",
        "management",
        "pain",
        "severe",
        "enough",
        "require",
        "daily",
        "opioid",
        "treatment",
        "alternative",
        "treatment",
        "option",
        "inadequate",
        "contact",
        "alex",
        "dasalla",
        "adasalla",
        "source",
        "collegium",
        "pharmaceutical",
        "inc"
    ]
}